FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - NYSE Delayed Price. Currency in USD
38.29
-0.25 (-0.65%)
At close: 4:02PM EDT

38.29
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close38.54
Open37.78
Bid38.31 x 800
Ask38.28 x 800
Day's Range37.59 - 38.36
52 Week Range30.99 - 53.40
Volume229,535
Avg. Volume218,432
Market Cap23.391B
Beta (3Y Monthly)1.93
PE Ratio (TTM)10.37
EPS (TTM)3.69
Earnings DateN/A
Forward Dividend & Yield0.63 (1.50%)
Ex-Dividend Date2019-05-17
1y Target Est47.06
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of FME.DE earnings conference call or presentation 2-May-19 1:30pm GMT

    Q1 2019 Fresenius Medical Care AG & Co KGaA Earnings Call

  • Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
    Zacks14 days ago

    Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

    Fresenius Medical (FMS) gains from solid international revenues in Q1.

  • Reuters18 days ago

    Fresenius makes solid start to year after turbulent 2018

    Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

  • GlobeNewswirelast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medical Care AG & Co. KGaA  - FMS

    Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS

    NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (''Fresenius'' or the ''Company'') (FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Fresenius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • GlobeNewswirelast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS

    Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • Fresenius Medical Care to pay $231M to resolve bribery charges
    American City Business Journals2 months ago

    Fresenius Medical Care to pay $231M to resolve bribery charges

    Fresenius Medical Care, a dialysis clinic operator, agreed Friday to pay $231 million in penalties to resolve allegations it paid bribes to win business deals in several countries, including Angola and Saudi Arabia.

  • Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?
    Insider Monkey2 months ago

    Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?

    Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Reuters2 months ago

    Fresenius Medical Care to pay $231 mln to resolve criminal, civil foreign bribery charges

    Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice Department said on Friday. The Justice Department agreed not to prosecute the company criminally in exchange for Fresenius paying a penalty of $84,715,273. The Securities and Exchange Commission, meanwhile, ordered the company to pay $147 million in disgorgement and prejudgment interest to settle the civil charges.

  • Reuters2 months ago

    Fresenius Medical Care says U.S. settlement will not affect 2019, 2020 results

    Fresenius Medical Care AG said that a $231.7 million U.S. settlement reached on Friday to resolve bribery allegations would have no impact on its 2019 and 2020 results because it had already made a financial ...

  • MarketWatch2 months ago

    Fresenius Medical Care to pay $231 million to settle bribery charges

    The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA , a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC. Fresenius was found to have violated the Foreign Corrupt Practices Act by falsifying documents as well as contracts and funneling bribes through third-party intermediaries. FMC paid nearly $30 million in bribes to government officials and others to procure business, the company said. "By engaging in widespread bribery schemes across multiple countries, the company prioritized profits over compliance in its dealings with foreign government officials," said Tracy Price, deputy chief of the SEC Enforcement Division's FCPA Unit, in a statement.

  • Fresenius Medical to Make Huge Investments, Competition Rife
    Zacks2 months ago

    Fresenius Medical to Make Huge Investments, Competition Rife

    Fresenius Medical (FMS) is likely to make huge investments in India and China.

  • Fresenius Medical's New Hemodialysis Software Gets FDA Nod
    Zacks2 months ago

    Fresenius Medical's New Hemodialysis Software Gets FDA Nod

    Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

  • Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
    Zacks2 months ago

    Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

    Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

  • The Wall Street Journal2 months ago

    [$$] Fresenius Medical Care Readies for US Dialysis Shift

    , Secretary of the U.S. Department of Health and Human Services, said he wanted kidney-care to shift to a more value-based approach, favoring prevention and home care, and making transplants and artificial kidneys more accessible.

  • Should Value Investors Pick Fresenius Medical (FMS) Stock?
    Zacks2 months ago

    Should Value Investors Pick Fresenius Medical (FMS) Stock?

    Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?
    Simply Wall St.2 months ago

    How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?

    If you want to know who really controls Fresenius Medical Care AG & Co. KGaA (ETR:FME), then you'll have to look at the makeup of its share registry. Large companiesRead More...

  • Reuters3 months ago

    U.S. seeks to cut dialysis costs with more home care versus clinics

    The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending. The U.S. Centers for Medicare and Medicaid Services (CMS), which provides Medicare health benefits to more than 55 million Americans, is looking at a trial payment design that would improve care in the early stages of kidney disease, increase access to kidney transplants and favor home dialysis over clinic-based treatment, CMS head Seema Verma told Reuters in an interview.

  • Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4
    Zacks3 months ago

    Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4

    Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.

  • PR Newswire3 months ago

    Fresenius Medical Care completes acquisition of NxStage Medical

    WALTHAM, Mass., Feb. 26, 2019 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, has successfully completed the acquisition of NxStage Medical, Inc. (NxStage), following approval by antitrust authorities in the United States. NxStage develops, produces and markets an innovative product portfolio of medical devices for use in home dialysis and critical care. The acquisition will enable Fresenius Medical Care to leverage its manufacturing, supply chain and marketing competencies across the dialysis products, services and Care Coordination businesses in a less labor- and capital-intensive care setting.

  • The Wall Street Journal3 months ago

    [$$] German Dialysis Firm Reaches Agreement in Bribery Probe

    German health-care firm Fresenius Medical Care AG said last week in a regulatory filing that it had reached an agreement in principle with U.S. authorities regarding a long-running foreign-bribery investigation that involved an anonymous whistleblower complaint. Fresenius said in the filing that it received communications beginning in 2012 that had alleged conduct outside the U.S. that might violate the Foreign Corrupt Practices Act or other antibribery laws. According to documents reviewed by The Wall Street Journal, an anonymous whistleblower sent an email in April 2012 to Fresenius managers and board members.

  • Reuters3 months ago

    FMC wraps up $2 bln acquisition of NxStage

    Germany's Fresenius Medical Care (FMC) wrapped up its $2 billion acquisition of U.S. home dialysis maker NxStage Medical on Friday, according to a U.S. Securities and Exchange Commission filing. The closure - some 18 months after FMC agreed to buy NxStage - paves the way for the world's biggest provider of dialysis services to scale up its home dialysis business by investing in new infrastructure, patient training and education.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FME.DE earnings conference call or presentation 20-Feb-19 2:30pm GMT

    Q4 2018 Fresenius Medical Care AG & Co KGaA Earnings Call